These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17269899)

  • 61. In silico approaches for predicting ADME properties of drugs.
    Yamashita F; Hashida M
    Drug Metab Pharmacokinet; 2004 Oct; 19(5):327-38. PubMed ID: 15548844
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001.
    Straub JO
    Toxicol Lett; 2002 Oct; 135(3):231-7. PubMed ID: 12270681
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Environmental risk assessment for new human pharmaceuticals in the European Union according to the draft guideline/discussion paper of January 2001.
    Straub JO
    Toxicol Lett; 2002 May; 131(1-2):137-43. PubMed ID: 11988366
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Challenges and directions for regulatory use of QSARs for predicting active pharmaceutical ingredients environmental toxicity.
    Sanderson H
    Curr Drug Saf; 2012 Sep; 7(4):309-12. PubMed ID: 23062243
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Adverse Outcome Pathways can drive non-animal approaches for safety assessment.
    Burden N; Sewell F; Andersen ME; Boobis A; Chipman JK; Cronin MT; Hutchinson TH; Kimber I; Whelan M
    J Appl Toxicol; 2015 Sep; 35(9):971-5. PubMed ID: 25943792
    [TBL] [Abstract][Full Text] [Related]  

  • 66. QSAR, Read-across and REACH.
    Barratt MD
    Altern Lab Anim; 2003 Nov; 31(5):463-5. PubMed ID: 15598173
    [No Abstract]   [Full Text] [Related]  

  • 67. Introduction to the EU REACH legislation.
    Grindon C; Combes R
    Altern Lab Anim; 2006 Mar; 34 Suppl 1():5-10. PubMed ID: 16555955
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Risk assessment of 'endocrine substances': guidance on identifying endocrine disruptors.
    Lewis RW
    Toxicol Lett; 2013 Dec; 223(3):287-90. PubMed ID: 24036001
    [TBL] [Abstract][Full Text] [Related]  

  • 69. QSARs in ecotoxicological risk assessment.
    de Roode D; Hoekzema C; de Vries-Buitenweg S; van de Waart B; van der Hoeven J
    Regul Toxicol Pharmacol; 2006 Jun; 45(1):24-35. PubMed ID: 16529851
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The use of computer models in pharmaceutical safety evaluation.
    Boyer S
    Altern Lab Anim; 2009 Nov; 37(5):467-75. PubMed ID: 20017577
    [TBL] [Abstract][Full Text] [Related]  

  • 71. FRAME and the Royal Commission on Environmental Pollution: common recommendations for assessing risks posed by chemicals under the EU REACH system.
    Combes RD; Dandrea J; Balls M
    Altern Lab Anim; 2003 Nov; 31(5):529-35. PubMed ID: 15598178
    [TBL] [Abstract][Full Text] [Related]  

  • 72. QSAR models for reproductive toxicity and endocrine disruption in regulatory use--a preliminary investigation.
    Jensen GE; Niemelä JR; Wedebye EB; Nikolov NG
    SAR QSAR Environ Res; 2008; 19(7-8):631-41. PubMed ID: 19061080
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.
    Chen M; Hong H; Fang H; Kelly R; Zhou G; Borlak J; Tong W
    Toxicol Sci; 2013 Nov; 136(1):242-9. PubMed ID: 23997115
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Overview of data and conceptual approaches for derivation of quantitative structure-activity relationships for ecotoxicological effects of organic chemicals.
    Bradbury SP; Russom CL; Ankley GT; Schultz TW; Walker JD
    Environ Toxicol Chem; 2003 Aug; 22(8):1789-98. PubMed ID: 12924578
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Integrated decision-tree testing strategies for mutagenicity and carcinogenicity with respect to the requirements of the EU REACH legislation.
    Combes R; Grindon C; Cronin MT; Roberts DW; Garrod JF
    Altern Lab Anim; 2008 Oct; 36 Suppl 1():43-63. PubMed ID: 19025331
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Novel technologies and an overall strategy to allow hazard assessment and risk prediction of chemicals, cosmetics, and drugs with animal-free methods.
    Leist M; Lidbury BA; Yang C; Hayden PJ; Kelm JM; Ringeissen S; Detroyer A; Meunier JR; Rathman JF; Jackson GR; Stolper G; Hasiwa N
    ALTEX; 2012; 29(4):373-88. PubMed ID: 23138508
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Alternative test methods in inhalation toxicology: challenges and opportunities.
    Costa DL
    Exp Toxicol Pathol; 2008 Jun; 60(2-3):105-9. PubMed ID: 18486462
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The challenge of reproductive and developmental toxicology under REACH.
    Scialli AR
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):244-50. PubMed ID: 18490093
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Computational approaches for skin sensitization prediction.
    Wilm A; Kühnl J; Kirchmair J
    Crit Rev Toxicol; 2018 Oct; 48(9):738-760. PubMed ID: 30488745
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology.
    Perkins R; Fang H; Tong W; Welsh WJ
    Environ Toxicol Chem; 2003 Aug; 22(8):1666-79. PubMed ID: 12924569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.